Role within the CfCWR
Anne Logan is the Principal Investigator in the Decorin Project
Other positions held
- Head of Neuroscience and Ophthalmology
- Director of Centre for Trauma Science Research
- Theme Lead for the NIHR Surgical Reconstruction and Microbiology Research Centre
- Theme Lead and member of the Operations Group for NIHR Trauma Management MedTech Co-operative (MIC)
- Member of the Scar Free Foundation RPMG
- PhD University of Birmingham, Neuroendocrinology
- PGCE University of Birmingham, Biological Sciences
- BSc University of London (1 st Class), Botany/Zoology
Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, RAICR, University of Birmingham
Professor Ann Logan received her BSc from the University of London in 1974 and PhD training in neuroendocrinology at the University of Birmingham between 1975 and 1978. After post-doctoral training at the University of Leeds and in the laboratories of Professor Roger Guillemin and Professor Andrew Baird at Scripps Hospital, La Jolla, CA, she established the Neurotrauma Group at the University of Birmingham in 1990, where she is currently Professor of Molecular Neuroscience and Head of Neuroscience and Ophthalmology within the College of Medicine and Dentistry. Her research interests centre upon the trophic regulation of injury responses.
Her work has generated more than 185 research publications on the roles, mechanisms and exploitation of growth factors in the injured tissues, with particular interests in neurotrauma of the eye. Professor Logan strives to translate scientific advancements into the clinical arena for patient benefit. For her own research she works closely with both clinicians and companies to initiate clinical trials of novel anti-scarring and reparative drugs. Professor Logan is also a key figure in the NIHR Surgical Reconstruction and Microbiology Research Centre (SRCMRC) which is also based in Birmingham at UHBFT and the University. She is PI for a number of major £multi-million translational projects related to the clinical development of anti-scarring technologies. In addition, she is also founder, director and CSO for a University of Birmingham spin-out company called Neuregenix Ltd, that offers neural drug screening services to large and small pharmaceutical and biotechnology companies.
0121 414 8854
Secretary: Nadene Bryan 0121 414 8855